Treatment strategy for hypopharyngeal cancer

From the viewpoint of the radiation oncologist

Katsumasa Nakamura, Yoshiyuki Shioyama, Satoru Nomoto, Ohga Saiji, Takashi Toba, Tadamasa Yoshitake, Hiroshi Honda, Shizuo Komune, Torahiko Nakashima, Yuichiro Kuratomi

研究成果: ジャーナルへの寄稿記事

抄録

Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

元の言語英語
ページ(範囲)305-308
ページ数4
ジャーナルToukeibu Gan
33
発行部数3
DOI
出版物ステータス出版済み - 1 1 2007

Fingerprint

Hypopharyngeal Neoplasms
Chemoradiotherapy
Therapeutics
Radiotherapy
Survival Rate
Radiation Oncologists
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

これを引用

Treatment strategy for hypopharyngeal cancer : From the viewpoint of the radiation oncologist. / Nakamura, Katsumasa; Shioyama, Yoshiyuki; Nomoto, Satoru; Saiji, Ohga; Toba, Takashi; Yoshitake, Tadamasa; Honda, Hiroshi; Komune, Shizuo; Nakashima, Torahiko; Kuratomi, Yuichiro.

:: Toukeibu Gan, 巻 33, 番号 3, 01.01.2007, p. 305-308.

研究成果: ジャーナルへの寄稿記事

Nakamura, K, Shioyama, Y, Nomoto, S, Saiji, O, Toba, T, Yoshitake, T, Honda, H, Komune, S, Nakashima, T & Kuratomi, Y 2007, 'Treatment strategy for hypopharyngeal cancer: From the viewpoint of the radiation oncologist', Toukeibu Gan, 巻. 33, 番号 3, pp. 305-308. https://doi.org/10.5981/jjhnc.33.305
Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Nomoto, Satoru ; Saiji, Ohga ; Toba, Takashi ; Yoshitake, Tadamasa ; Honda, Hiroshi ; Komune, Shizuo ; Nakashima, Torahiko ; Kuratomi, Yuichiro. / Treatment strategy for hypopharyngeal cancer : From the viewpoint of the radiation oncologist. :: Toukeibu Gan. 2007 ; 巻 33, 番号 3. pp. 305-308.
@article{e764aa8f72424fa39952529f7921ec4c,
title = "Treatment strategy for hypopharyngeal cancer: From the viewpoint of the radiation oncologist",
abstract = "Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4{\%} vs 90.9{\%}). Local control with laryngeal voice preservation was achieved in 8 (88.9{\%}) of 9 patients with stage I disease, and in 23 (67.6{\%}) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9{\%} in T1, 59.7{\%} in T2, 46.0{\%} in T3, and 34.9{\%} in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.",
author = "Katsumasa Nakamura and Yoshiyuki Shioyama and Satoru Nomoto and Ohga Saiji and Takashi Toba and Tadamasa Yoshitake and Hiroshi Honda and Shizuo Komune and Torahiko Nakashima and Yuichiro Kuratomi",
year = "2007",
month = "1",
day = "1",
doi = "10.5981/jjhnc.33.305",
language = "English",
volume = "33",
pages = "305--308",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "3",

}

TY - JOUR

T1 - Treatment strategy for hypopharyngeal cancer

T2 - From the viewpoint of the radiation oncologist

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Nomoto, Satoru

AU - Saiji, Ohga

AU - Toba, Takashi

AU - Yoshitake, Tadamasa

AU - Honda, Hiroshi

AU - Komune, Shizuo

AU - Nakashima, Torahiko

AU - Kuratomi, Yuichiro

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

AB - Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

UR - http://www.scopus.com/inward/record.url?scp=85009628185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009628185&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.33.305

DO - 10.5981/jjhnc.33.305

M3 - Article

VL - 33

SP - 305

EP - 308

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -